When do the patents on LIPOSYN III 10% expire, and when will generic LIPOSYN III 10% be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	LIPOSYN III 10%	soybean oil	INJECTABLE;INJECTION	018969-001	Sep 24, 1984		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 28, 2026

LIPOSYN III 10% investment scenario and fundamentals analysis (patent, exclusivity, FDA status, and generic risk)

Executive summary: LIPOSYN III 10% (soybean oil, egg phospholipid, glycerin) is an older intravenous lipid emulsion used to deliver essential fatty acids in patients who require parenteral nutrition. As a legacy product, the investment profile depends less on next-cycle innovation and more on (1) whether meaningful Orange Book exclusivity or unexpired patents remain for the listed strengths/formulations, (2) how crowded the competitive landscape is from interchangeable lipid emulsions, and (3) substitution risk based on formulary access and supply. Without a verified LIPOSYN III Orange Book record and active patent litigation/settlement docket tied to the NDA, a complete, decisions-grade investment and IP risk map cannot be produced.

What patents protect LIPOSYN III 10% (lipid emulsion) and how strong is the patent estate?

A decisions-grade patent estate requires: NDA-linked Orange Book listings, each patent’s expiration date, and claim scope (composition, method of use, and manufacturing). For legacy parenteral nutrition lipid emulsions, the key investor question is whether the remaining intellectual property blocks direct generic substitution or only covers specific process details.

What would typically be listed for an intravenous lipid emulsion NDA

For products like LIPOSYN III, the Orange Book estate, when present, usually partitions into:

Composition-of-matter (lipid emulsion formulation composition, ratios, phospholipid system)
Method-of-use (nutritional support indications)
Manufacturing or process patents (emulsion particle size, homogenization/sterility handling, stability)

Investment implication of a “thin” vs “thick” estate

Thin estate: faster generic or “AB-rated” alternatives, pressure on acquisition pricing and margin.
Thick estate: longer runway for cash-flow protection but higher litigation and licensing cost if entry work is needed.

Jurisdiction and enforcement reality

For IP-driven protection in older products, the practical constraint is whether patent enforcement can stop an FDA-approved AB substitute and whether supply-chain readiness supports launch. Lipid emulsions also face chemistry, manufacturing, and controls (CMC) barriers that may slow challengers even where patents are narrow.

When does LIPOSYN III 10% lose exclusivity (Orange Book exclusivity and patent expiration timing)?

Timing for loss of exclusivity is normally anchored on three items:

Patent expirations (composition, method-of-use, and process)
Regulatory exclusivity (e.g., Hatch-Waxman exclusivity categories)
Pediatric exclusivity or orphan-related exclusivity if applicable

Featured snippet answer

Loss of exclusivity is determined by the latest expiration date among Orange Book patents and any applicable regulatory exclusivity tied to the NDA.

Investment implication

For an older product, investors underwrite a “near-term substitution window” if the last patent or exclusivity expires soon. If no unexpired Orange Book patents exist, the product’s economic life is driven by:

hospital purchasing behavior,
wholesaler contracting,
product availability and supply continuity,
and competition from clinically similar lipid emulsions.

How many patents cover LIPOSYN III 10% and what are the remaining expiration dates?

A credible count requires enumerating Orange Book-listed patents by:

patent number
type (listed drug patent categories)
expiration date
assignee
status (active, expired, subject to litigation)

Without verified Orange Book patent listings for LIPOSYN III 10% tied to the exact NDA and strength, a correct patent count and expiration table cannot be provided.

What formulations are protected for LIPOSYN III 10% (composition, particle size, and stability)?

Lipid emulsions are sensitive to CMC attributes:

droplet size distribution
stability under storage and infusion conditions
phospholipid composition and emulsifier characteristics
sterility assurance and aseptic processing
fill-finish and container closure system

Why formulation scope drives generic risk

Even when patents are narrow, regulators may scrutinize equivalence of key characteristics. Investors should treat CMC comparability as a major practical barrier, especially for intravenously administered emulsions where stability and infusion performance can matter clinically.

What generic entry risks exist for LIPOSYN III 10% (AB-rated substitutes and Paragraph IV strategy)?

A typical generic entry risk model for an NDA-rated drug uses:

Orange Book status (unexpired patents)
FDA pathway likely to be pursued (505(j) vs other)
whether a Paragraph IV certification is feasible
risk that challengers rely on limited differences in composition or process

Investment conclusion tied to entry risk

High entry risk compresses margins and increases working-capital volatility.
Low entry risk supports longer cash-flow durability but can raise acquisition cost if buyers pay for presumed exclusivity.

Which companies are challenging LIPOSYN III 10% (Paragraph IV filings and litigation challengers)?

A litigation-based risk map requires:

Paragraph IV notice dates
court dockets
settlement agreement terms
admitted or denied infringement theories
any FDA approval delays tied to litigation

Without confirmed Paragraph IV notices, docket numbers, and settlement documents tied to LIPOSYN III 10%, companies challenging the product cannot be listed reliably.

What patent litigation affects LIPOSYN III 10% (court cases, settlements, and injunction threats)?

Investor relevance is driven by:

whether courts enjoin generic approval,
whether settlements create “first-filer” exclusivity protections,
and whether the settlement includes market-splitting or licensing economics.

Without verified litigation history for the specific NDA/patent set covering LIPOSYN III 10%, litigation impact cannot be quantified.

What is the Orange Book status of LIPOSYN III 10% (listed drug, patents, and exclusivity categories)?

Orange Book status determines whether:

the product is protected by listed patents,
the listed patents are expired,
and the entry route is blocked or open.

A complete Orange Book status table cannot be produced here without verified Orange Book listings for LIPOSYN III 10%.

How does LIPOSYN III 10% compare with competing intravenous lipid emulsions (clinical substitutability and supply risk)?

Investment fundamentals for older parenteral nutrition products are often driven by practical substitutability rather than long-horizon patent gaps.

Substitution drivers

hospital pharmacy formulary inclusion and therapeutic interchange policies
guideline alignment for essential fatty acid delivery in parenteral nutrition
safety profile and infusion-related tolerability
availability and backorder history (supply risk can lock in switching even when branded)

Competitive pressure sources

other FDA-approved lipid emulsions used for parenteral nutrition
generic or “therapeutic alternative” products that are AB-rated to the listed drug
procurement-driven switching by group purchasing organizations

What is LIPOSYN III 10% FDA regulatory status (approval pathway, labeling, and current manufacturing standing)?

For investment underwriting, regulators’ status questions include:

NDA approval basis (original vs supplement)
current manufacturing sites and inspection history
labeling for indications and limitations
any safety communications that influence switching

A verified FDA status profile cannot be produced here without direct linkage to the specific NDA and current FDA/drug listing data for LIPOSYN III 10%.

What commercial revenue exposure exists for LIPOSYN III 10% (market size, payer mix, and hospital usage)?

Revenue modeling requires:

unit sales or volume estimates by channel (GPO, retail specialty, institutional)
average net price and discounting assumptions
patient mix and dosing patterns in parenteral nutrition wards
contract structure and tender cycles

A decisions-grade commercial analysis cannot be produced without verified sales metrics tied to LIPOSYN III 10%.

How strong is the business case for acquiring or licensing LIPOSYN III 10% (deal mechanics and ROI drivers)?

For a legacy intravenous product, licensing and acquisition value typically depends on:

unexpired IP tail (if any)
exclusivity and litigation leverage (if any)
manufacturing capability and CMC transfer feasibility
ability to secure supply contracts and maintain service levels
cost of regulatory maintenance and post-approval commitments

Deal structure that typically matters

license with minimum sales milestones or supply reimbursement
technology transfer tied to CMC equivalence
IP assignment or field-of-use carve-outs
supply agreement with quality and service-level terms

Without verified exclusivity and status, the ROI drivers cannot be quantified for LIPOSYN III 10%.

Generic launch scenarios for LIPOSYN III 10% (what happens after exclusivity ends)?

Scenario modeling usually uses:

time to generic approval and launch
expected price erosion curve in hospital tender markets
share shift driven by interchangeability and formulary preferences
inventory pipeline clearing time

Generic launch scenarios require confirmation of Orange Book patent expiration and FDA entry pathway feasibility. Those inputs are not available in this response.

Key Takeaways

LIPOSYN III 10% is an older intravenous lipid emulsion used in parenteral nutrition; the investment case is typically driven by formulary access, supply reliability, and substitution dynamics.
Patent and exclusivity underwriting requires verified Orange Book listings and any active litigation tied to the specific NDA and strengths.
Without Orange Book and FDA-linked data, a complete fundamentals model covering exclusivity timelines, patent counts, and generic risk cannot be constructed in a decision-grade format.

FAQs

Is LIPOSYN III 10% considered interchangeable with other lipid emulsions for parenteral nutrition on hospital formularies?
How do CMC equivalence requirements (droplet size, stability, and sterilization) affect generic approval risk for intravenous lipid emulsions?
What is the typical hospital procurement impact when a lipid emulsion experiences supply interruptions?
How does patent scope (composition vs method-of-use vs manufacturing process) change litigation leverage for legacy parenteral nutrition products?
What settlement terms commonly govern market entry timing after Paragraph IV challenges for older injectable products?

References

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-07-28).
U.S. FDA. Drugs@FDA. (Accessed 2026-07-28).

LIPOSYN III 10% Drug Patent Profile

When do Liposyn Iii 10% patents expire, and when can generic versions of Liposyn Iii 10% launch?

AI Deep Research

Questions you can ask:

Summary for LIPOSYN III 10%

US Patents and Regulatory Information for LIPOSYN III 10%